The developer of a drug for the rare multiple system atrophy, Alterity will launch a pivotal phase III trial after a go-ahead ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Multiple system atrophy (MSA) is a rare and fatal brain disorder with no available treatment or cure, attacking the nervous system, balance, and the ability to move. The disease in many ways resembles ...
Multiple system atrophy Parkinsonian type (MSA-P) is a rare neurodegenerative disease that progresses over time. It can cause problems with movement and coordination, digestion, bladder control, ...
Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results